Intensive glycemic control and the risk of end-stage renal disease: an ADVANCE in the management of diabetes?

Published

Journal Article

Posttrial follow-up of participants randomized to intensive versus standard glycemic control in the ADVANCE trial has demonstrated a significant benefit of intensive glycemic control on the risk of end-stage renal disease. In a more detailed analysis, intensive glycemic control appears to be of benefit only before the development of clinically evident kidney disease or in patients with documented early-stage chronic kidney disease.

Full Text

Duke Authors

Cited Authors

  • Wyatt, CM; Cattran, DC

Published Date

  • July 2016

Published In

Volume / Issue

  • 90 / 1

Start / End Page

  • 8 - 10

PubMed ID

  • 27312437

Pubmed Central ID

  • 27312437

Electronic International Standard Serial Number (EISSN)

  • 1523-1755

Digital Object Identifier (DOI)

  • 10.1016/j.kint.2016.05.002

Language

  • eng

Conference Location

  • United States